X

Trial Profile

A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glesatinib (Primary) ; Mocetinostat (Primary) ; Nivolumab (Primary) ; Sitravatinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Mirati Therapeutics

Most Recent Events

10 Apr 2024 Status changed from completed to discontinued.
24 Feb 2023 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Journal of Thoracic Oncology.
24 Feb 2023 Results (n=156) assessing efficacy and safety of sitravatinib with nivolumab in patients with non-squamous non-small cell lung cancer, published in the Journal of Thoracic Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com